The impact of COVID‐19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients
The COVID‐19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding the real impact of the pandemic in current practice. The present study aimed to capture patients' and healthcare professionals' ex...
Saved in:
| Published in | Journal of neuroendocrinology Vol. 34; no. 10; pp. e13196 - n/a |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.10.2022
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0953-8194 1365-2826 1365-2826 |
| DOI | 10.1111/jne.13196 |
Cover
Loading…
| Abstract | The COVID‐19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding the real impact of the pandemic in current practice. The present study aimed to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post‐pandemic environment. Physicians and nurses working in ENETS Centers of Excellence or other hospitals with high volume of NET patients (n = 48), as well as NET patients residing worldwide (n = 353), were asked to respond to two online anonymous surveys addressing different aspects of NET care. Deferred diagnoses, delayed surveillance procedures and postponed elective surgeries were among the main negative consequences of the COVID‐19 outbreak according to 40%, 54% and 46% of healthcare professionals (HPs) respectively. Somatostatin analogs were increasingly used as bridging strategy for delaying surgery based on the views of 31% of HPs and were self‐injected or delivered by home care services more frequently than before the initiation of the pandemic (53% of patients during the pandemic vs. 44% before the pandemic). Multidisciplinary tumor boards kept their usual schedule according to 58% of HPs, but were held virtually in the 77% of cases. The contact with healthcare professionals was maintained by remote methods more often than in the past (69% of patients), but only 34% of patients (59% among subjects < 41 years) would prefer telemedicine to face‐to‐face consultations in the future. New health policy measures should guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID‐19 pandemic in the next months. Pros and cons of telemedicine should be carefully weighted before systematic implementation.
The COVID‐19 outbreak has added complexity in the management of patients with NETs. This study aims to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post‐pandemic environment. New health policy measures must guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID‐19 pandemic. |
|---|---|
| AbstractList | The COVID-19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding the real impact of the pandemic in current practice. The present study aimed to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post-pandemic environment. Physicians and nurses working in ENETS Centers of Excellence or other hospitals with high volume of NET patients (n = 48), as well as NET patients residing worldwide (n = 353), were asked to respond to two online anonymous surveys addressing different aspects of NET care. Deferred diagnoses, delayed surveillance procedures and postponed elective surgeries were among the main negative consequences of the COVID-19 outbreak according to 40%, 54% and 46% of healthcare professionals (HPs) respectively. Somatostatin analogs were increasingly used as bridging strategy for delaying surgery based on the views of 31% of HPs and were self-injected or delivered by home care services more frequently than before the initiation of the pandemic (53% of patients during the pandemic vs. 44% before the pandemic). Multidisciplinary tumor boards kept their usual schedule according to 58% of HPs, but were held virtually in the 77% of cases. The contact with healthcare professionals was maintained by remote methods more often than in the past (69% of patients), but only 34% of patients (59% among subjects < 41 years) would prefer telemedicine to face-to-face consultations in the future. New health policy measures should guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID-19 pandemic in the next months. Pros and cons of telemedicine should be carefully weighted before systematic implementation. The COVID‐19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding the real impact of the pandemic in current practice. The present study aimed to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post‐pandemic environment. Physicians and nurses working in ENETS Centers of Excellence or other hospitals with high volume of NET patients (n = 48), as well as NET patients residing worldwide (n = 353), were asked to respond to two online anonymous surveys addressing different aspects of NET care. Deferred diagnoses, delayed surveillance procedures and postponed elective surgeries were among the main negative consequences of the COVID‐19 outbreak according to 40%, 54% and 46% of healthcare professionals (HPs) respectively. Somatostatin analogs were increasingly used as bridging strategy for delaying surgery based on the views of 31% of HPs and were self‐injected or delivered by home care services more frequently than before the initiation of the pandemic (53% of patients during the pandemic vs. 44% before the pandemic). Multidisciplinary tumor boards kept their usual schedule according to 58% of HPs, but were held virtually in the 77% of cases. The contact with healthcare professionals was maintained by remote methods more often than in the past (69% of patients), but only 34% of patients (59% among subjects < 41 years) would prefer telemedicine to face‐to‐face consultations in the future. New health policy measures should guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID‐19 pandemic in the next months. Pros and cons of telemedicine should be carefully weighted before systematic implementation. The COVID‐19 outbreak has added complexity in the management of patients with NETs. This study aims to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post‐pandemic environment. New health policy measures must guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID‐19 pandemic. The COVID‐19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding the real impact of the pandemic in current practice. The present study aimed to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post‐pandemic environment. Physicians and nurses working in ENETS Centers of Excellence or other hospitals with high volume of NET patients (n = 48), as well as NET patients residing worldwide (n = 353), were asked to respond to two online anonymous surveys addressing different aspects of NET care. Deferred diagnoses, delayed surveillance procedures and postponed elective surgeries were among the main negative consequences of the COVID‐19 outbreak according to 40%, 54% and 46% of healthcare professionals (HPs) respectively. Somatostatin analogs were increasingly used as bridging strategy for delaying surgery based on the views of 31% of HPs and were self‐injected or delivered by home care services more frequently than before the initiation of the pandemic (53% of patients during the pandemic vs. 44% before the pandemic). Multidisciplinary tumor boards kept their usual schedule according to 58% of HPs, but were held virtually in the 77% of cases. The contact with healthcare professionals was maintained by remote methods more often than in the past (69% of patients), but only 34% of patients (59% among subjects < 41 years) would prefer telemedicine to face‐to‐face consultations in the future. New health policy measures should guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID‐19 pandemic in the next months. Pros and cons of telemedicine should be carefully weighted before systematic implementation. The COVID-19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding the real impact of the pandemic in current practice. The present study aimed to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post-pandemic environment. Physicians and nurses working in ENETS Centers of Excellence or other hospitals with high volume of NET patients (n = 48), as well as NET patients residing worldwide (n = 353), were asked to respond to two online anonymous surveys addressing different aspects of NET care. Deferred diagnoses, delayed surveillance procedures and postponed elective surgeries were among the main negative consequences of the COVID-19 outbreak according to 40%, 54% and 46% of healthcare professionals (HPs) respectively. Somatostatin analogs were increasingly used as bridging strategy for delaying surgery based on the views of 31% of HPs and were self-injected or delivered by home care services more frequently than before the initiation of the pandemic (53% of patients during the pandemic vs. 44% before the pandemic). Multidisciplinary tumor boards kept their usual schedule according to 58% of HPs, but were held virtually in the 77% of cases. The contact with healthcare professionals was maintained by remote methods more often than in the past (69% of patients), but only 34% of patients (59% among subjects < 41 years) would prefer telemedicine to face-to-face consultations in the future. New health policy measures should guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID-19 pandemic in the next months. Pros and cons of telemedicine should be carefully weighted before systematic implementation.The COVID-19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding the real impact of the pandemic in current practice. The present study aimed to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post-pandemic environment. Physicians and nurses working in ENETS Centers of Excellence or other hospitals with high volume of NET patients (n = 48), as well as NET patients residing worldwide (n = 353), were asked to respond to two online anonymous surveys addressing different aspects of NET care. Deferred diagnoses, delayed surveillance procedures and postponed elective surgeries were among the main negative consequences of the COVID-19 outbreak according to 40%, 54% and 46% of healthcare professionals (HPs) respectively. Somatostatin analogs were increasingly used as bridging strategy for delaying surgery based on the views of 31% of HPs and were self-injected or delivered by home care services more frequently than before the initiation of the pandemic (53% of patients during the pandemic vs. 44% before the pandemic). Multidisciplinary tumor boards kept their usual schedule according to 58% of HPs, but were held virtually in the 77% of cases. The contact with healthcare professionals was maintained by remote methods more often than in the past (69% of patients), but only 34% of patients (59% among subjects < 41 years) would prefer telemedicine to face-to-face consultations in the future. New health policy measures should guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID-19 pandemic in the next months. Pros and cons of telemedicine should be carefully weighted before systematic implementation. The COVID‐19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding the real impact of the pandemic in current practice. The present study aimed to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post‐pandemic environment. Physicians and nurses working in ENETS Centers of Excellence or other hospitals with high volume of NET patients ( n = 48), as well as NET patients residing worldwide ( n = 353), were asked to respond to two online anonymous surveys addressing different aspects of NET care. Deferred diagnoses, delayed surveillance procedures and postponed elective surgeries were among the main negative consequences of the COVID‐19 outbreak according to 40%, 54% and 46% of healthcare professionals (HPs) respectively. Somatostatin analogs were increasingly used as bridging strategy for delaying surgery based on the views of 31% of HPs and were self‐injected or delivered by home care services more frequently than before the initiation of the pandemic (53% of patients during the pandemic vs. 44% before the pandemic). Multidisciplinary tumor boards kept their usual schedule according to 58% of HPs, but were held virtually in the 77% of cases. The contact with healthcare professionals was maintained by remote methods more often than in the past (69% of patients), but only 34% of patients (59% among subjects < 41 years) would prefer telemedicine to face‐to‐face consultations in the future. New health policy measures should guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID‐19 pandemic in the next months. Pros and cons of telemedicine should be carefully weighted before systematic implementation. The COVID‐19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding the real impact of the pandemic in current practice. The present study aimed to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post‐pandemic environment. Physicians and nurses working in ENETS Centers of Excellence or other hospitals with high volume of NET patients ( n = 48), as well as NET patients residing worldwide ( n = 353), were asked to respond to two online anonymous surveys addressing different aspects of NET care. Deferred diagnoses, delayed surveillance procedures and postponed elective surgeries were among the main negative consequences of the COVID‐19 outbreak according to 40%, 54% and 46% of healthcare professionals (HPs) respectively. Somatostatin analogs were increasingly used as bridging strategy for delaying surgery based on the views of 31% of HPs and were self‐injected or delivered by home care services more frequently than before the initiation of the pandemic (53% of patients during the pandemic vs. 44% before the pandemic). Multidisciplinary tumor boards kept their usual schedule according to 58% of HPs, but were held virtually in the 77% of cases. The contact with healthcare professionals was maintained by remote methods more often than in the past (69% of patients), but only 34% of patients (59% among subjects < 41 years) would prefer telemedicine to face‐to‐face consultations in the future. New health policy measures should guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID‐19 pandemic in the next months. Pros and cons of telemedicine should be carefully weighted before systematic implementation. The COVID‐19 outbreak has added complexity in the management of patients with NETs. This study aims to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post‐pandemic environment. New health policy measures must guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID‐19 pandemic. |
| Author | Cives, Mauro Bouvier, Catherine Hernando, Jorge Lamarca, Angela Pavel, Marianne Caplin, Martyn |
| AuthorAffiliation | 1 Department of Biomedical Sciences and Human Oncology University of Bari “Aldo Moro” Bari Italy 2 Department of Medical Oncology Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology Barcelona Spain 3 Department of Medical Oncology The Christie NHS Foundation, Manchester; Division of Cancer Sciences, University of Manchester Manchester UK 5 Neuroendocrine Tumor Unit Royal Free Hospital London UK 4 International Neuroendocrine Cancer Alliance (INCA) Boston Massachusetts USA 6 Department of Medicine 1, Endocrinology Friedrich Alexander Universität Erlangen‐Nürnberg Erlangen Germany |
| AuthorAffiliation_xml | – name: 3 Department of Medical Oncology The Christie NHS Foundation, Manchester; Division of Cancer Sciences, University of Manchester Manchester UK – name: 6 Department of Medicine 1, Endocrinology Friedrich Alexander Universität Erlangen‐Nürnberg Erlangen Germany – name: 1 Department of Biomedical Sciences and Human Oncology University of Bari “Aldo Moro” Bari Italy – name: 5 Neuroendocrine Tumor Unit Royal Free Hospital London UK – name: 2 Department of Medical Oncology Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology Barcelona Spain – name: 4 International Neuroendocrine Cancer Alliance (INCA) Boston Massachusetts USA |
| Author_xml | – sequence: 1 givenname: Mauro orcidid: 0000-0002-3013-1816 surname: Cives fullname: Cives, Mauro email: mauro.cives@uniba.it organization: University of Bari “Aldo Moro” – sequence: 2 givenname: Jorge surname: Hernando fullname: Hernando, Jorge organization: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology – sequence: 3 givenname: Angela surname: Lamarca fullname: Lamarca, Angela organization: The Christie NHS Foundation, Manchester; Division of Cancer Sciences, University of Manchester – sequence: 4 givenname: Catherine surname: Bouvier fullname: Bouvier, Catherine organization: International Neuroendocrine Cancer Alliance (INCA) – sequence: 5 givenname: Martyn surname: Caplin fullname: Caplin, Martyn organization: Royal Free Hospital – sequence: 6 givenname: Marianne surname: Pavel fullname: Pavel, Marianne organization: Friedrich Alexander Universität Erlangen‐Nürnberg |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36072989$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks1uEzEQxy1URNPCgRdAlri0h7T2ej9sDkhVCFBUpQcCV8vrnU0c7dpbe7coNx6hz9JH4klwPlpBBZYlSzO__39GnjlCB9ZZQOg1JWc0nvOVhTPKqMifoRFleTZOeJIfoBERGRtzKtJDdBTCihBaZIy8QIcsJ0UiuBih-_kSsGk7pXvsajy5_n754dfPOyqws7iPuVZZtYAW7DZvYfAObOW0NxZwP7TOB3wym86_nr7DFxYb24O3qjfOqgbHeLSczaaTOQ6Dv4X1xmQT7SISPQNWtsJLUE2_1MoD7ryrIYStPODeQ-TsItbtHyUv0fM6JuHV_j1G3z5O55PP46vrT5eTi6uxTlOWj2sgDIpKiKKo67IWGUmSNM0rrtKSlwzKgpaiquJlKS8E0aTSeUkqnumCaeDsGL3f-XZD2UKlY22vGtl50yq_lk4Z-XfGmqVcuFspCp7HEw1O9gbe3QwQetmaoKFplAU3BJkUlPKUiDyJ6Nsn6MoNfvMHkUpEllHOaKTe_NnRYysP44zA-Q7Q3oXgoZba9NthxAZNIymRm4WRcWHkdmGi4vSJ4sH0X-ze_YdpYP1_UH6ZTXeK3yd90mU |
| CitedBy_id | crossref_primary_10_1111_jne_13380 crossref_primary_10_1111_jne_13486 crossref_primary_10_1007_s13304_024_01942_z |
| Cites_doi | 10.3322/caac.21493 10.3390/jcm9113633 10.1001/jamaoncol.2020.6178 10.1093/jncics/pkaa102 10.1016/j.annonc.2021.12.006 10.1016/j.annonc.2020.03.304 10.1093/jnci/djaa168 10.1007/s12020-020-02564-2 10.1111/jne.13041 10.1016/j.ejca.2020.11.037 10.1001/jamaoncol.2020.0980 10.1200/GO.20.00225 10.1007/s40618-020-01393-4 10.1002/cncr.33243 10.1016/j.ejca.2021.06.029 10.3390/medicina57121287 10.1016/S1470‐2045(20)30096‐6 10.1016/S0140‐6736(20)30183‐5 10.1016/S1470-2045(21)00573-8 |
| ContentType | Journal Article |
| Copyright | 2022 The Authors. published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology. 2022 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology. 2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2022 The Authors. published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology. – notice: 2022 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology. – notice: 2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7QR 7TK 8FD FR3 K9. P64 7X8 5PM |
| DOI | 10.1111/jne.13196 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Technology Research Database ProQuest Health & Medical Complete (Alumni) Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Technology Research Database MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| DocumentTitleAlternate | Cives et al |
| EISSN | 1365-2826 |
| EndPage | n/a |
| ExternalDocumentID | PMC9786666 36072989 10_1111_jne_13196 JNE13196 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Ipsen Biopharmaceuticals – fundername: ; |
| GroupedDBID | --- -DZ .3N .GA .Y3 05W 0R~ 10A 1OB 1OC 24P 29L 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAFWJ AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABIVO ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCUC ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AETEA AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHEFC AHMBA AIACR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBC EBD EBS EBX EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FYBCS FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YFH ZGI ZXP ZZTAW ~IA ~WT AAHHS AAYXX ACCFJ AEEZP AEQDE AIWBW AJBDE CITATION CGR CUY CVF ECM EIF NPM 7QP 7QR 7TK 8FD FR3 K9. P64 7X8 5PM |
| ID | FETCH-LOGICAL-c4436-fe03e7d9977ffbf95022446d8a4b8b3eb71b9dd9dd348790c0dc6b0d85c73ce83 |
| IEDL.DBID | DR2 |
| ISSN | 0953-8194 1365-2826 |
| IngestDate | Thu Aug 21 18:40:23 EDT 2025 Fri Jul 11 05:11:32 EDT 2025 Mon Jul 14 09:46:50 EDT 2025 Mon Jul 21 06:02:16 EDT 2025 Tue Jul 01 02:01:42 EDT 2025 Thu Apr 24 22:50:17 EDT 2025 Sun Jul 06 04:45:29 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | telemedicine SARS-CoV-2 carcinoids vaccination |
| Language | English |
| License | Attribution 2022 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4436-fe03e7d9977ffbf95022446d8a4b8b3eb71b9dd9dd348790c0dc6b0d85c73ce83 |
| Notes | Funding information Ipsen Biopharmaceuticals ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Funding information Ipsen Biopharmaceuticals |
| ORCID | 0000-0002-3013-1816 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjne.13196 |
| PMID | 36072989 |
| PQID | 2729551831 |
| PQPubID | 34202 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9786666 proquest_miscellaneous_2711840962 proquest_journals_2729551831 pubmed_primary_36072989 crossref_citationtrail_10_1111_jne_13196 crossref_primary_10_1111_jne_13196 wiley_primary_10_1111_jne_13196_JNE13196 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | October 2022 |
| PublicationDateYYYYMMDD | 2022-10-01 |
| PublicationDate_xml | – month: 10 year: 2022 text: October 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Oxford – name: Hoboken |
| PublicationTitle | Journal of neuroendocrinology |
| PublicationTitleAlternate | J Neuroendocrinol |
| PublicationYear | 2022 |
| Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
| References | 2021; 57 2020; 6 2021; 7 2021; 5 2021; 33 2021; 22 2021; 44 2021; 113 2020; 31 2020; 395 2021; 127 2020; 9 2021; 144 2020; 21 2021; 154 2021; 71 2021; 74 2018; 68 e_1_2_9_20_1 e_1_2_9_11_1 e_1_2_9_22_1 e_1_2_9_10_1 e_1_2_9_21_1 e_1_2_9_13_1 e_1_2_9_24_1 e_1_2_9_12_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_18_1 Quero G (e_1_2_9_19_1) 2021; 74 |
| References_xml | – volume: 6 start-page: 799 year: 2020 end-page: 808 article-title: Effect of cancer on clinical outcomes of patients with COVID‐19: a meta‐analysis of patient data publication-title: JCO Glob Oncol – volume: 68 start-page: 471 issue: 6 year: 2018 end-page: 487 article-title: Gastroenteropancreatic neuroendocrine tumors publication-title: CA Cancer J Clin – volume: 154 start-page: 246 year: 2021 end-page: 252 article-title: Coronavirus disease 2019 in patients with neuroendocrine neoplasms: preliminary results of the INTENSIVE study publication-title: Eur J Cancer – volume: 57 start-page: 1287 issue: 12 year: 2021 article-title: Self‐Administration of Long‐Acting Somatostatin Analogues in NET patients‐does it affect the clinical outcome? publication-title: Medicina (Kaunas) – volume: 22 start-page: 1669 issue: 12 year: 2021 end-page: 1680 article-title: On Covid study group. Prevalence and impact of COVID‐19 sequelae on treatment and survival of patients with cancer who recovered from SARS‐CoV‐2 infection: evidence from the OnCovid retrospective, multicentre registry study publication-title: Lancet Oncol – volume: 9 start-page: 3633 issue: 11 year: 2020 article-title: Professional assessment of the impact of COVID‐19 on handling NET patients publication-title: J Clin Med – volume: 5 issue: 2 year: 2021 article-title: A systematic review and meta‐analysis of cancer patients affected by a novel coronavirus publication-title: JNCI Cancer Spectr – volume: 33 start-page: 340 issue: 3 year: 2021 end-page: 346 article-title: COVID‐19 and cancer consortium. COVID‐19 vaccination and breakthrough infections in patients with cancer publication-title: Ann Oncol – volume: 71 start-page: 14 issue: 1 year: 2021 end-page: 19 article-title: Impact of the COVID‐19 pandemic on neuroendocrine tumour services in England publication-title: Endocrine – volume: 31 start-page: 36394 issue: 7 year: 2020 end-page: 36398 article-title: Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up publication-title: Ann Oncol – volume: 113 start-page: 371 issue: 4 year: 2021 end-page: 380 article-title: Clinical characteristics and outcomes of COVID‐19‐infected cancer patients: a systematic review and meta‐analysis publication-title: J Natl Cancer Inst – volume: 44 start-page: 989 issue: 5 year: 2021 end-page: 994 article-title: Impact of the SARS‐CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) publication-title: J Endocrinol Invest – volume: 395 start-page: 497 issue: 10223 year: 2020 end-page: 506 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan China publication-title: Lancet – volume: 21 start-page: 335 issue: 3 year: 2020 article-title: Cancer patients in SARS‐CoV‐2 infection: a nationwide analysis in China publication-title: Lancet Oncol – volume: 74 start-page: 1 year: 2021 end-page: 12 article-title: Quantitative assessment of the impact of COVID‐19 pandemic on pancreatic surgery: an Italian multicenter analysis of 1423 cases from 10 tertiary referral centers publication-title: Updates Surg – volume: 144 start-page: 200 year: 2021 end-page: 214 article-title: Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID‐19 era publication-title: Eur J Cancer – volume: 6 start-page: 1108 issue: 7 year: 2020 end-page: 1110 article-title: SARS‐CoV‐2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China publication-title: JAMA Oncol – volume: 127 start-page: 266 issue: 2 year: 2021 end-page: 274 article-title: Multivariate mortality analyses in COVID‐19: comparing patients with cancer and patients without cancer in Louisiana publication-title: Cancer – volume: 7 start-page: 220 issue: 2 year: 2021 end-page: 227 article-title: Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID‐19 infection publication-title: JAMA Oncol – volume: 33 issue: 10 year: 2021 article-title: The psychological impact of COVID‐19 pandemic on patients with neuroendocrine tumors: between resilience and vulnerability publication-title: J Neuroendocrinol – ident: e_1_2_9_14_1 doi: 10.3322/caac.21493 – ident: e_1_2_9_17_1 doi: 10.3390/jcm9113633 – ident: e_1_2_9_8_1 doi: 10.1001/jamaoncol.2020.6178 – ident: e_1_2_9_9_1 doi: 10.1093/jncics/pkaa102 – ident: e_1_2_9_12_1 doi: 10.1016/j.annonc.2021.12.006 – ident: e_1_2_9_22_1 doi: 10.1016/j.annonc.2020.03.304 – ident: e_1_2_9_3_1 – ident: e_1_2_9_10_1 doi: 10.1093/jnci/djaa168 – ident: e_1_2_9_18_1 doi: 10.1007/s12020-020-02564-2 – ident: e_1_2_9_21_1 doi: 10.1111/jne.13041 – ident: e_1_2_9_24_1 doi: 10.1016/j.ejca.2020.11.037 – ident: e_1_2_9_20_1 – ident: e_1_2_9_5_1 doi: 10.1001/jamaoncol.2020.0980 – ident: e_1_2_9_11_1 doi: 10.1200/GO.20.00225 – ident: e_1_2_9_16_1 doi: 10.1007/s40618-020-01393-4 – ident: e_1_2_9_7_1 doi: 10.1002/cncr.33243 – volume: 74 start-page: 1 year: 2021 ident: e_1_2_9_19_1 article-title: Quantitative assessment of the impact of COVID‐19 pandemic on pancreatic surgery: an Italian multicenter analysis of 1423 cases from 10 tertiary referral centers publication-title: Updates Surg – ident: e_1_2_9_15_1 doi: 10.1016/j.ejca.2021.06.029 – ident: e_1_2_9_23_1 doi: 10.3390/medicina57121287 – ident: e_1_2_9_6_1 doi: 10.1016/S1470‐2045(20)30096‐6 – ident: e_1_2_9_2_1 doi: 10.1016/S0140‐6736(20)30183‐5 – ident: e_1_2_9_4_1 – ident: e_1_2_9_13_1 doi: 10.1016/S1470-2045(21)00573-8 |
| SSID | ssj0017530 |
| Score | 2.38764 |
| Snippet | The COVID‐19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding... The COVID-19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e13196 |
| SubjectTerms | carcinoids COVID-19 Health care Humans Neuroendocrine tumors Neuroendocrine Tumors - therapy Original Pandemics Patients SARS-CoV-2 Somatostatin Surgery Surveys Telemedicine Telemedicine - methods Translational and Clinical Neuroendocrinology vaccination |
| Title | The impact of COVID‐19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjne.13196 https://www.ncbi.nlm.nih.gov/pubmed/36072989 https://www.proquest.com/docview/2729551831 https://www.proquest.com/docview/2711840962 https://pubmed.ncbi.nlm.nih.gov/PMC9786666 |
| Volume | 34 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZKT1yAUn5CS2UQQsshKyfxxjGcVstWpRIBwRb1gBT5L2oF61SbBKmceASehUfiSbCdxNqlICGkHCJ7HDvKjD3jfPMZgCdoojCVhIQpUyjEkYhDxjEPqZI0VghJ4tDur_P06AQfn05Ot8CLIRem44fwG27WMtx8bQ2c8XrdyLUaR1aBzPxrsVrWIXrnqaMsASXqePaS0Kx6uGcVciieoeXmWnTFwbyKk1z3X90CdHgTfByG3uFOPo3bho_F199YHf_z3W6BG71jCqedJu2ALaVvg92pNkH58hI-hQ4q6vbgd8EPo1ywy6-EVQlnbz68evnz2_eIwkpD41HCpQfV2HrHmam0rIRNNYRNu6xWNRzl88X7Z8_hVMPz9W1JaMrNI_N8PlvAul19UZf2Iba0J4GtIdMSnnnkGrxY4xepocPOmxXZ9Nv4JnfAyeF8MTsK-8MfQoFxkoalQokikhr_tCx5SSfW2cCpzBjmGU8UJxGnUporMTEXRQJJkXIks4kgiVBZchds60qr-wCaQoFUyZhiGLMMUZkSrEhKFWammAdgNKhBIXpmdHtAx-fCR0haFe57BOCxF73o6ED-JLQ_6FLRzwh1EZsoxrLfJVEAHvlqY8v2Bw3TqmqtTOQC7jQOwL1O9XwvSWo53jMaALKhlF7A8oRv1ujzM8cXTklmglQzrJHTub8PvDjO5-7mwb-L7oHrsc0IcfjGfbDdrFr10PhpDT8A12L89sCZ5S8jPz7K |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZKOcCFv_ITKGAQQsshKyfxJjHislq22pY2SLBFvaDIf1Grdp1qkyCVE4_As_BIPAm2k1i7FCSElENkj2NHmbFnJp8_A_ACjSQmIkn8mErk44CHPmWY-UQKEkqERGLR7gdZPDvEe0ejow3wpt8L0_JDuISbsQw7XxsDNwnpVStXchgYDboCrpoTvW1A9cGRRxkKStQy7UW-XvdwxytkcTx90_XV6JKLeRkpuerB2iVo5yb43A--RZ6cDpuaDfnX33gd__ftboEbnW8Kx60y3QYbUt0BW2Ol4_LFBXwJLVrUpuG3wA-tX7DdYgnLAk7ef9p9-_Pb94DAUkHtVMKFw9WYekubKZUoudltCOtmUS4rOMim84-vXsOxgiermUmoy_Ujs2w6mcOqWX6RF-YhprTjga0gVQIeO_AaPF-hGKmghc_rRVn3W7smd8HhznQ-mfnd-Q8-xziK_UKiSCaCaBe1KFhBRsbfwLFIKWYpiyRLAkaE0Fekwy6COBI8ZkikI55EXKbRPbCpSiUfAKgLOZIFpZJiTFNERJxgmcREYqqLmQcGvR7kvCNHN2d0nOUuSFIyt9_DA8-d6HnLCPInoe1emfJuUqjyUAcyhgAvCjzwzFVrczb_aKiSZWNkAhtzx6EH7re653qJYkPznhIPJGta6QQMVfh6jTo5tpThJEl1nKqHNbBK9_eB53vZ1N48_HfRp-DabH6wn-_vZu8egeuh2SBi4Y7bYLNeNvKxdttq9sRa5y9TKkIO |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLVKkRAbXuURKGAQQsMiIyfxOHFZjeahtkBAMEVdIEV-Ra1gnNFkglRWfEK_hU_iS7Cdh2YoSAgpi8i-iR3l3Phe5_gYgGdooDCVcewTppCPAxH6jGPuUyVpqBCSsWO7v0nJ_hE-PB4cb4GX7VqYWh-im3CznuG-19bBFzJfd3Kt-oEF0CVwGROUWEiP33faUVaBEtVCe5Fvhj3cyAo5Gk976eZgdCHCvEiUXA9g3Qg0vQ4-tX2viSef-9WK98W332Qd__PhboBrTWQKhzWUboItpW-BnaE2Wfn8DD6HjivqJuF3wA-DLlgvsIRFDkdvPx6Mf34_DygsNDQhJZx3rBpb70QzlZaFsGsN4aqaF8sS9tLJ7MOLPTjU8HR9XhKacnPLNJ2MZrCsll_Vmb2JLW1UYEvItIQnHXUNLtYERkroyPNmSDbtrrpLboOj6WQ22veb3R98gXFE_FyhSMWSmgA1z3lOBzbawEQmDPOER4rHAadSmiMySRdFAklBOJLJQMSRUEl0B2zrQqt7AJpCgVTOmGIYswRRSWKsYkIVZqaYe6DXwiATjTS63aHjS9alSFpl7n144Glnuqj1QP5ktNtiKWs-CWUWmjTGyt9FgQeedNXGme0fGqZVUVmbwGXcJPTA3Rp6XSsRsSLvCfVAvAHKzsAKhW_W6NMTJxhO48RkqaZbPYe5v3c8O0wn7uT-v5s-BlfejafZ64P01QNwNbSrQxzXcRdsr5aVemhithV_5HzzF4q5QMY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+impact+of+COVID%E2%80%9019+on+the+management+of+neuroendocrine+tumors+%28NETS%29%3A+An+international+NET+CONNECT+survey+of+NET+patients+and+healthcare+professionals+treating+net+patients&rft.jtitle=Journal+of+neuroendocrinology&rft.au=Cives%2C+Mauro&rft.au=Hernando%2C+Jorge&rft.au=Lamarca%2C+Angela&rft.au=Bouvier%2C+Catherine&rft.date=2022-10-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=0953-8194&rft.eissn=1365-2826&rft.volume=34&rft.issue=10&rft_id=info:doi/10.1111%2Fjne.13196&rft_id=info%3Apmid%2F36072989&rft.externalDocID=PMC9786666 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0953-8194&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0953-8194&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0953-8194&client=summon |